Skip to main content

Table 3 The prevalence and association of tested 21 founder/recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 genes with the risk of BOT and low-grade ovarian cancer

From: Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor

Gene

Controls, n=1743 (%)

Cases

BOT, n=102 (%)

Ovarian cancer G1, n=167 (%)

BRCA1

5 (0.29)

0 (0.00)

4 (2.40)

OR (95% CI)

p value

ref.

-

8.53 (2.09–32.54)

0.005

BRCA2

0 (0.00)

1 (0.98)

1 (0.60)

OR (95% CI)

p value

ref.

-

-

RAD51C

3 (0.17)

0 (0.00)

0 (0.00)

OR (95% CI)

 p value

ref.

-

-

PALB2

3 (0.17)

0 (0.00)

2 (1.20)

OR (95% CI)

 p value

ref.

-

7.03 (0.92–42.72)

0.03

CHEK2

PTT

10 (0.57)

1 (0.98)

1 (0.60)

OR (95% CI)

p value

ref.

1.72 (0.099.09)

0.61

1.04 (0.065.5)

0.97

missense mutation

(c.470T>C)

OR (95% CI)

p value

97 (5.57)

ref.

11 (10.78)

2.05 (1.013.81)

0.03

13 (7.78)

1.43 (0.752.53)

0.24